Recently, cancer immunotherapy, particularly immune checkpoint therapy targeting programmed cell death-1 (PD-1), PD-1-ligand-1 (PD-L1), and cytotoxic T-lymphocyte antigen 4 (CTLA-4), has become a new treatment option for various types of cancers [2,3]. Here, PDCD1 is linked to cancer.